Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 5, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on June 1, 2006:
- Previous Holdings: 17,411,245 Ordinary Share ADRs
- New Holdings: 17,377,725 Ordinary Share ADRs
- Average Price: $55.67
Two directors, Dr. J P Garnier and Dr. M Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding the notification of the transaction.
Key Facts for Investor Verification
- Verify the impact of the 33,520 ADR reduction in the US Retirement Savings Plan on overall insider ownership percentages.
- Confirm the specific nature of the "fund movement" that triggered the change in share count.
- Review the full list of directors and connected persons to assess if other similar transactions occurred outside this specific notification.